Trubion Pharmaceuticals, Inc. Securities Litigation
On or around 09/05/2011 (Stipulation and order of dismissal (voluntary dismissal))
Filing Date: October 04, 2010
According to a press release dated October 05, 2010, the complaint charges Trubion and Trubion’s board of directors with, among other things, violations of the Securities Exchange Act of 1934 and Rule 14a-9. In particular, the complaint alleges that the defendants have issued materially false and misleading statements regarding the proposed transaction wherein Trubion intends to merge with Emergent.
On December 01, 2010, the Court issued a Corrected Stipulation and Order Staying Case until after the State Court decides whether to finally approve a settlement.
On September 09, 2011, this case was dismissed pursuant to Federal Rule of Civil Procedure 41(a) and 41(b), after submission of a Motion to Dismiss by the Plaintiff.
Company & Securities Information
Defendant: Trubion Pharmaceuticals, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: TRBN
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.